
InVivo Therapeutics (Nasdaq: NVIV) on Tuesday said it plans to raise about $28 million via a public offering of over …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

